Guo Li
Guo Li has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Xinzhi Zhou
College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China
3 shared publications- Yuan Yao
Zhejiang University
3 shared publications Guanglin Zhu
Xianghu Laboratory, Hangzhou, China
2 shared publicationsHongru Ma
College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China
2 shared publications- Xiaoxiang Hu
China Agricultural University
2 shared publications - Xingxu Huang
The Key Laboratory of Pancreatic Diseases of Zhejiang Province the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
2 shared publications
Latest Publications
- Open Access
- 27 June 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Programmable aging function-related mitochondrial DNA 5-methylcytosine (m5C) modification with a TALE-directed methyltransferase
Mitochondrial epigenetic editing offers a potential strategy for modulating disease-causing mitochondrial genes while leaving the underlying DNA sequence unchanged. In this study, we present MEE, a mitochondrial epigenetic editor consisting of mitochondrion-targeted TALE modules fused to Dnmt3A and Dnmt3L methyltransferases. MEE efficiently directed site-specific 5mC methylation within cellular mitochondrial DNA with low detectable off-target activity under the tested conditions. MEE-mediated methylation at the C12191 (H) site exceeded 53% and was associated with an approximately 95% reduction in steady-state MT-ND5 mRNA levels in human cells. Notably, MEE increased methylation at the aging-associated C11168 (H) site by 11.76% in vivo, leading to reduced MT-ND4 expression in the targeted brain region and altered plasma levels of t-Tau and NFL in mice. These findings demonstrate that MEE provides a tool for precise epigenetic engineering of mitochondrial DNA, enabling experimental interrogation of specific 5mC modifications and exploration of the functional roles of mitochondrial DNA methylation in aging-associated diseases.
- 27 June 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Open AccessProgrammable aging function-related mitochondrial DNA 5-methylcytosine (m5C) modification with a TALE-directed methyltransferase
Mitochondrial epigenetic editing offers a potential strategy for modulating disease-causing mitochondrial genes while leaving the underlying DNA sequence unchanged. In this study, we present MEE, a mitochondrial epigenetic editor consisting of mitochondrion-targeted TALE modules fused to Dnmt3A and Dnmt3L methyltransferases. MEE efficiently directed site-specific 5mC methylation within cellular mitochondrial DNA with low detectable off-target activity under the tested conditions. MEE-mediated methylation at the C12191 (H) site exceeded 53% and was associated with an approximately 95% reduction in steady-state MT-ND5 mRNA levels in human cells. Notably, MEE increased methylation at the aging-associated C11168 (H) site by 11.76% in vivo, leading to reduced MT-ND4 expression in the targeted brain region and altered plasma levels of t-Tau and NFL in mice. These findings demonstrate that MEE provides a tool for precise epigenetic engineering of mitochondrial DNA, enabling experimental interrogation of specific 5mC modifications and exploration of the functional roles of mitochondrial DNA methylation in aging-associated diseases.
- 3 October 2024
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 30 (6) , 1-16
AI-Driven Design of Cell-Penetrating Peptides for Therapeutic Biotechnology
- 3 October 2024
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 30 (6) , 1-16
AI-Driven Design of Cell-Penetrating Peptides for Therapeutic Biotechnology
- 19 September 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (2) , 280-290
Compact RNA editors with natural miniature Cas13j nucleases
Clustered regularly interspaced short palindromic repeats–Cas13 effectors are used for RNA editing but the adeno-associated virus (AAV) packaging limitations because of their big sizes hinder their therapeutic application. Here we report the identification of the Cas13j family, with LepCas13j (529 aa) and ChiCas13j (424 aa) being the smallest and most highly efficient variants for RNA interference. The miniaturized Cas13j proteins enable the development of compact RNA base editors. Chi-RESCUE-S, by fusing dChiCas13j with hADAR2dd, demonstrates high efficiency and specificity in A-to-G and C-to-U conversions. Importantly, this system is compatible with single-AAV packaging without the need for protein sequence truncation. It successfully corrected pathogenic mutations, such as APOC3D65N and SCN9AR896Q, to the wild-type forms. In addition, we developed an optimized system, Chi-RESCUE-S-mini3, which pioneered efficient in vivo C-to-U RNA editing of PCSK9 in mice through single-AAV delivery, resulting in reduced total cholesterol levels. These results highlight the potential of Cas13j to treat human diseases.
- 19 September 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (2) , 280-290
Compact RNA editors with natural miniature Cas13j nucleases
Clustered regularly interspaced short palindromic repeats–Cas13 effectors are used for RNA editing but the adeno-associated virus (AAV) packaging limitations because of their big sizes hinder their therapeutic application. Here we report the identification of the Cas13j family, with LepCas13j (529 aa) and ChiCas13j (424 aa) being the smallest and most highly efficient variants for RNA interference. The miniaturized Cas13j proteins enable the development of compact RNA base editors. Chi-RESCUE-S, by fusing dChiCas13j with hADAR2dd, demonstrates high efficiency and specificity in A-to-G and C-to-U conversions. Importantly, this system is compatible with single-AAV packaging without the need for protein sequence truncation. It successfully corrected pathogenic mutations, such as APOC3D65N and SCN9AR896Q, to the wild-type forms. In addition, we developed an optimized system, Chi-RESCUE-S-mini3, which pioneered efficient in vivo C-to-U RNA editing of PCSK9 in mice through single-AAV delivery, resulting in reduced total cholesterol levels. These results highlight the potential of Cas13j to treat human diseases.
- Open Access
- 1 March 2020
- Published by Elsevier in Journal of Genetics and Genomics
WITHDRAWN: Porcine reproductive and respiratory syndrome virus (PRRSV) inhibition with engineered Cas13d
- 1 March 2020
- Published by Elsevier in Journal of Genetics and Genomics
Open AccessWITHDRAWN: Porcine reproductive and respiratory syndrome virus (PRRSV) inhibition with engineered Cas13d